Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Texarkana Gazette

Pfizer to make generic Viagra pill available beginning Monday

TRENTON, N.J.-The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales ...

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.
Fierce Biotech

Pfizer adds to Seagen scrap heap with another early cancer candidate cull

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
BioSpace

Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test

Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...